Main Content

Development of a high throughput screening assay for Ewing sarcoma oncoprotein

Support our mission and make a difference for the sarcoma community.

Development of a high throughput screening assay for Ewing sarcoma oncoprotein

Ewing’s Sarcoma presents a unique opportunity to develop tumor specific targeted therapy due to a pathognomonic chromosomal translocation. Proper function of EWS-FLl1, protein product of this chromosomal translocation, is required for tumor cell survival. We will develop a cell based High Throughput Screening assay. We will generate Ewing’s cell-lines expressing two fluorescent proteins. GFP will be expressed from an EWS-FLl1 regulated promoter and RFP from an unrelated negative control promoter. In this dual color HTS assay, a small molecule library will be screened for inhibiting GFP but not RFP, which will provide lead compounds for novel Ewing’s Sarcoma therapies.

section